

Enzalutamide PROSPER

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Reviewed, but not qualified for an ESMO-MCBS credit

Serious and disabling adverse effects



Other adjustments



Enzalutamide PROSPER

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
Therapeutic Indication: Treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC)
Experimental Arm: Enzalutamide + ADT (androgen deprivation therapy)
Control Arm: ADT + placebo



